Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
15 studies found for:    " March 28, 2012":" April 27, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
" March 28, 2012":" April 27, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated The Mochudi Prevention Project ART Protocol
Condition: HIV Infections
Intervention: Drug: highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine
2 Unknown † Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
Conditions: Human Immunodeficiency Virus (HIV);   Tuberculosis (TB);   Latent Tuberculosis Infection (LTI)
Intervention: Drug: Isoniazid
3 Completed Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Condition: HIV Infection
Interventions: Drug: Tenofovir, Emtricitabine, Lopinavir/r;   Drug: Tenofovir, Emtricitabine, Raltegravir
4 Active, not recruiting Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-MAG vaccine;   Biological: IL-12 pDNA adjuvant;   Biological: VSV HIV gag vaccine;   Biological: Placebo;   Device: Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
5 Active, not recruiting Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
Condition: HIV Infections
Interventions: Biological: GEO-D03 DNA vaccine;   Biological: MVA/HIV62B (MVA62B) vaccine;   Biological: Placebo for GEO-D03 DNA;   Biological: Placebo for MVA62B:
6 Unknown † Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Condition: HIV
Intervention: Drug: Lopinavir/ritonavir 800 mg / 200mg
7 Completed Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda
Conditions: HIV;   Tuberculosis
Intervention: Other: Cellular Phone Text Message Formats
8 Recruiting Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Condition: HIV
Intervention: Drug: Tesamorelin for injection
9 Completed Experimental Analysis of HIV Risk Assessment Reactivity in South African Clinics
Condition: HIV Prevention and Assessment Reactivity
Interventions: Behavioral: Detailed baseline interview, enhanced HIV intervention;   Behavioral: General baseline interview, enhanced HIV intervention;   Behavioral: No baseline interview, enhanced HIV intervention;   Behavioral: Detailed baseline interview, standard of care intervention;   Behavioral: General baseline interview, standard of care intervention;   Behavioral: No baseline interview, standard of care intervention
10 Unknown †
Has Results 		Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg twice daily;   Drug: dolutegravir placebo twice daily;   Drug: Open-label dolutegravir 50mg twice daily
11 Active, not recruiting The Health Access and Recovery Peer Program
Conditions: Hypertension;   Arthritis;   Coronary Artery Disease;   Hepatitis;   Diabetes;   Asthma;   Hyperlipidemia;   HIV
Intervention: Behavioral: HARP Intervention
12 Recruiting Vascular Subphenotypes of Lung Disease in HIV & COPD
Condition: Pulmonary Artery Hypertension
Intervention:
13 Active, not recruiting HIV Prevention Intervention for Young Transgender Women
Condition: Sexual Transmission of Infection
Interventions: Behavioral: HIV prevention intervention;   Behavioral: Diet and Nutrition
14 Recruiting Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
Conditions: Anal Cancer;   Cervical Cancer;   Lung Cancer;   Lymphoma
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: medical chart review
15 Completed
Has Results 		Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
Condition: Cardiovascular Disease
Interventions: Drug: Efavirenz;   Drug: Rilpivirine
To Top

† Indicates status has not been verified in more than two years